Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results

Rhea-AI Summary

Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical company, will host a live webcast on April 3, 2023, at 4:30 p.m. Eastern time to discuss its 2022 financial results and provide a business update. The financial results will be released on March 31, 2023. The company's focus is on developing treatments for eye diseases with significant unmet needs, such as advanced age-related macular degeneration and Stargardt disease. Interested parties can join the webcast through the provided link, and a replay will be accessible for 90 days post-event.

Positive

• Company focuses on significant unmet medical needs in eye diseases.
• Scheduled webcast to discuss 2022 financial results indicates transparency to investors.

Negative

• None.

SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical needs, will host a live webcast on Monday, April 3, 2023, at 4:30 p.m. Eastern time to discuss the Company’s financial results for the full year ended December 31, 2022, and provide a general business update. The financial results will be issued in a press release on Friday, March 31, 2023.

Webcast Information:

Date:	Monday, April 3, 2023
Time:	4:30 p.m. Eastern time (1:30 a.m. Pacific time)
Webcast Link:	https://lifescievents.com/event/belite-bio-event/

Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available approximately two hours after the event for 90 days.

About Belite Bio

Belite Bio is a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical needs, such as advanced age-related macular degeneration (commonly known as Geographic Atrophy or advanced Dry AMD) and Stargardt disease, and metabolic diseases. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu /ir@belitebio.com
Tim McCarthy /tim@lifesciadvisors.com

FAQ

What is the date and time of Belite Bio's upcoming webcast regarding their 2022 financial results?

The webcast will take place on April 3, 2023, at 4:30 p.m. Eastern time.

When will Belite Bio release its financial results for the year 2022?

Belite Bio will release its financial results on March 31, 2023.

What is the focus of Belite Bio's drug development?

Belite Bio targets eye diseases such as advanced age-related macular degeneration and Stargardt disease.

How can investors access the replay of the Belite Bio webcast?

The replay will be available approximately two hours after the event for 90 days.